BioInteractions (Booth 2906) has launched Surface-Active Systems (SAS), a pioneering new category of high-performance, zero-leaching coating solutions designed to improve implant performance, enhance patient safety, and evolve therapeutic outcomes.
“For many clinicians and patients, the benefits of Surface-Active Systems coatings remain largely unknown,” explains Nicholas Inston, President-Elect of the Vascular Access Society and Consultant Surgeon in Vascular Access & Transplantation at Queen Elizabeth Hospital Birmingham. “By preventing infection and reducing clot formation at the device surface, these coatings address two of the most serious risks associated with dialysis catheter use: bloodstream infections and thrombosis—including thrombin sheath formation, a common cause of catheter dysfunction and reduced dialysis efficiency.
Surface-active systems represent a paradigm shift for medical device coating technologies. Within this category, durable surface treatments are tailored to enhance patient outcomes through improved device longevity as well as increased device efficacy, with better safety of medical devices.
Patients benefit from improved implant performance, superior interventional results and an enhanced quality of life. Overall, they are suitable for a wide variety of medical devices and are compatible with a broad range of device geometries and substrates ranging from small metal implants to larger polymer-based systems.
